Latest filing published 17 Sept 2026 for Mineralys Therapeutics, Inc., €31k.
Filing timeline
BuySaleInsider track record
Daphne Karydas: trading record in brief
All filings by Daphne Karydas on record concern Mineralys Therapeutics, Inc. Over a trading history stretching from 13 November 2025 to 15 September 2026, the count stands at 8 filings.
No open-market purchase appears, only 4 sales worth €734k. The rest of the record consists of 1 share grant and 3 option exercises. In 2026 alone, the filings show no purchases and 2 sales.
On 17 September 2026 came the latest disclosure, an option exercise for €31k in Mineralys Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Daphne Karydas
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 3,000 shares@ US$12.020.0015% mcap7.8% of flowCommon StockSEC:0001816952-26-000005:0
- 3,000 shares@ US$28.580.0038% mcap15.7% of flowCommon StockSEC:0001816952-26-000005:1
- 3,000 shares@ US$12.027.8% of flowCommon StockSEC:0001816952-26-000002:0
- 3,000 shares@ US$25.0016.3% of flowCommon StockSEC:0001816952-26-000002:1
- 6,200 shares0Common StockSEC:0001933414-26-000042:0
- 15,000 shares@ US$10.2033.1% of flowCommon StockSEC:0001933414-25-000150:0
6 of 6 declarations
